Human high molecular weight-melanoma-associated antigen: Utility for detection of metastatic melanoma in sentinel lymph nodes

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3401-3407

  Goto, Yasufumi ^a   Ferrone, Soldano ^c   Arigami, Takaaki ^a   Kitago, Minoru ^a   Tanemura, Atsushi ^a   Sunami, Eiji ^a   Nguyen, Sandy L ^a   Turner, Roderick R ^b   Morton, Donald L ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b SAINT JOHN'S HEALTH CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOLECULAR WEIGHT MELANOMA ANTIGEN; MELAN A; MELANOMA ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY HMB 45; UNCLASSIFIED DRUG; CALCIUM BINDING PROTEIN; HMW MAA; HMW-MAA; MART1 ANTIGEN; MELANOMA SPECIFIC ANTIGENS; MELANOMA-SPECIFIC ANTIGENS; PARAFFIN; S100P PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; MICROMETASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; BIOSYNTHESIS; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR;

ANTIGENS, NEOPLASM; CALCIUM-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM PROTEINS; PARAFFIN EMBEDDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 50349103346     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1842     Document Type: Article

References (24)

1. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
2. Morton DL,Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307-17.
3. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-63; discussion 463-5.
4. Cochran AJ, Wen DR, Herschman HR. Occult melanoma in lymph nodes detected by antiserum to S-100 protein. Int J Cancer 1984;34:159-63.
5. Yu LL, FlotteTJ, Tanabe KK, et al. Detection of microscopic melanoma metastases in sentinel lymph. nodes. Cancer 1999;86:617-27.
6. Gibbs JF, Huang PP, Zhang PJ, Kraybill WG, Cheney R. Accuracy of pathologic techniques for the diagnosis of metastatic melanoma in sentinel lymph nodes. Ann Surg Oncol 1999;6:699-704.
7. Messina JL, Glass LF, Cruse CW, Berman C, Ku NK, Reintgen DS. Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol 1999;23:686-90.
8. Bostick PJ, Chatterjee S, Chi DD, et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 1998;16:2632-40.
9. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 2004;24:267-96.
10. Shidham VB, Qi DY, Acker S, et al. Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45. Am J Surg Pathol 2001;25:1039-46.
11. Karimipour DJ, Lowe L, Su L, et al Standard immu-nostains for melanoma in sentinel lymph node specimens: which ones are most useful? J Am Acad Dermatol 2004;50:759-64.
12. Takeuchi H, Morton DL, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004:22:2671-80.
13. Giacomini P, Natali P, Ferrone S. Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. J Immunol 1985;135:696-702.
14. Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S. Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma 1989;8:85-95.
15. Koyanagi K, O'Day SJ, Gonzalez R, et al. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res 2006;12:1137-43.
16. Goto Y, Matsuzaki Y, Kurihara S, et al. A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res 2006;66:4443-9.
17. Fitzgibbons PL, Chaurushiya PS, Nichols PW, Chandrasoma PT, Martin SE. Primary mucosal malignant melanoma: an immunohistochemical study of 12 cases with comparison to cutaneous and metastatic melanomas. Hum Pathol 1989;20:269-72.
18. Yu CH, Chen HH, Liu CM, et al. HMB-45 may be a more sensitive maker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanomas. J Oral Pathol Med 2005;34:540-5.
19. Prasad ML, Jungbluth AA, Iversen K, Huvos AG, Busam KJ. Expression of melanocytic differentiation markers in malignant melanomas of the oral and sinonasal mucosa. Am J Surg Pathol 2001;25:782-7.
20. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986;123:195-203.
21. Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology 1998;32:139-46.
22. Jungbluth AA, Busam KJ, Gerald WL, et al. A103: an anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol 1998;22:595-602.
23. Busam KJ, Iversen K, Coplan KA, et al. Immunore-activity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol1998;22:57-63.
24. Busam KJ, Chen YT, Old LJ, et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol 1998;22:976-82.